Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 8.2% year on year to $207.6 million. Its non-GAAP profit of $1.14 per share was 32.8% above analysts’ consensus estimates.

Is now the time to buy AMPH? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Amphastar Pharmaceuticals’ most recent quarter saw revenue and profits exceed Wall Street expectations, yet the market responded negatively, with shares trading down after the announcement. Management attributed the quarter’s performance to robust sales from BAQSIMI and Primatene MIST, as well as contributions from new product launches like ipratropium bromide and teriparatide. However, ongoing remediation efforts at the IMS manufacturing facility led to increased operational costs and affected the release of certain products, exerting pressure on gross margins. CFO Bill Peters noted, “Gross margin decreased during the quarter, primarily driven by the impact of lower net pricing on certain products and higher manufacturing expenses, including costs associated with the remediation efforts at our IMS manufacturing facility.”

Looking forward, Amphastar Pharmaceuticals is centering its growth strategy on expanding its commercial portfolio and advancing its development pipeline, with a particular focus on complex generics and biosimilars. Management expects continued headwinds from pricing pressures, especially related to BAQSIMI, and ongoing higher manufacturing expenses as IMS remediation continues. The company is preparing for a potential 2027 launch of its insulin aspart biosimilar, which could become a significant driver if approved. Executive Vice President Tony Marrs cautioned, “We do not think we will get back to the pricing that we had previously because of this double-dipping. Even the 3% price increase this year does not fully offset that,” highlighting persistent pricing challenges. Amphastar’s ability to manage regulatory compliance and bring new products to market will be pivotal in shaping future results.

Key insights from management’s remarks

Management pointed to strong commercial execution and new product launches as key drivers, while also outlining how manufacturing remediation and pricing pressures influenced results.

• BAQSIMI prescription growth: BAQSIMI, a glucagon nasal powder for severe hypoglycemia, delivered record sales driven by increased prescription volumes. Management credited targeted marketing campaigns and patient outreach for the uptick but emphasized ongoing pricing headwinds from commercial discounts and duplicate 340B pharmacy discounts, which have improved but remain a factor.
• Primatene MIST momentum: Primatene MIST, an over-the-counter asthma inhaler, posted higher sales due to both a recent price increase and increased unit volumes. In-store demand remained strong, and management highlighted the product’s resilience across multiple distribution channels.
• Recent product launches: Ipratropium bromide and teriparatide, both launched within the past year, contributed meaningfully to portfolio growth. Ipratropium bromide’s market share is expected to grow further as Amphastar remains the sole generic in its segment, while teriparatide stabilized the "other" category of pharmaceutical product sales.
• IMS remediation impact: Ongoing remediation at the IMS manufacturing facility, following an FDA warning letter, resulted in higher manufacturing expenses and delayed product releases, reducing sales of several IMS-produced items. Management noted that these operational issues, rather than demand, drove the shortfall in some product lines.
• Lidocaine and API sales: Amphastar benefited from supply shortages at competitors for lidocaine, leading to increased sales, while its ANP subsidiary’s active pharmaceutical ingredient (API) business showed steady, though somewhat lumpy, growth. Management expects demand for lidocaine to persist but flagged capacity constraints due to competing demands at the facility.

Drivers of future performance

Amphastar’s outlook is shaped by ongoing portfolio expansion, pipeline advancement, and the resolution of manufacturing and pricing challenges.

• Ongoing pricing pressure: Management expects continued pricing headwinds, especially for BAQSIMI, due to the persistence of duplicate 340B discounts and rebates. Even with incremental price increases, net pricing is not expected to recover to previous levels, and these pressures are likely to impact gross margins in the near term.
• IMS facility remediation: The company continues to prioritize corrective actions at its IMS manufacturing site, which is expected to raise costs and limit product volumes into 2027. While progress has been made, management does not forecast a return to full operating capacity until mid-2027, with incremental expenses of $2-3 million per quarter anticipated.
• Pipeline launches and market growth: Amphastar is advancing its insulin aspart biosimilar program for a potential 2027 launch, and ongoing development of proprietary and complex generic products remains a core focus. The company expects new launches to help offset pricing and manufacturing headwinds, but competitive intensity in biosimilars and generics could limit upside.

Catalysts in upcoming quarters

Looking ahead, the StockStory team will monitor (1) progress in resolving IMS facility remediation and its effect on manufacturing costs and product availability, (2) sustained prescription growth for BAQSIMI and Primatene MIST despite persistent pricing and discounting pressures, and (3) the timeline and regulatory progress of the insulin aspart biosimilar and other pipeline launches. Additional attention will be paid to management’s execution on backlog reduction and market share gains for recently launched products.

Amphastar Pharmaceuticals currently trades at $27.11, down from $27.66 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

High quality stocks for all market conditions

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.